Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

Robert Knobler | Marija Geroldinger-Simić | Alexander Kreuter
Nicolas Hunzelmann | Pia Moinzadeh | Franco Rongioletti
Christopher Denton | Luc Mouton | Maurizio Cutolo | Vanessa Smith
Armando Gabrielli | Martine Bagot | Anne B. Olesen | Ivan Foeldvari
Ahmad Jalili | Veli Matti Kähräri | Sarolta Kárpáti | Kristian Kofod
Malgorzata Olszewska | Jaana Panelius | Pietro Quaglino | Julien Seneschal
Michael Sticherling | Cord Sunderkötter | Adrian Tanew | Peter Wolf
Margitta Worm | Anna Skrok | Lidia Rudnicka | Thomas Krieg

Abstract

The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).

SCLEROMYXOEDEMA

Introduction

Scleromyxoedema, also known as diffuse/generalized and sclerodermoid lichen myxoedematosus or Arndt-Gottron disease, is a primary cutaneous mucinosis characterized by a generalized, papular and sclerodermodfolliculitis, cutaneous eruption that usually occurs in association with monoclonal gamopathy. Affected patients develop numerous waxy, firm papules and plaques that demonstrate mucin deposition, increased fibroblast proliferation and fibrosis on histological grounds. Systemic manifestations may involve the cardiovascular, gastrointestinal, pulmonary, musculoskeletal, renal or nervous systems and may lead to significant morbidity and mortality.

Scleromyxoedema should be distinguished from localized lichen myxoedematosus, a form of lichen myxoedematosus that presents with waxy, firm papules and plaques involving limited areas. Unlike scleromyxoedema, sclerotic features, systemic involvement and monoclonal gamopathy are absent in localized lichen myxoedematosus. Systemic sclerosis...
and scleroedema are additional disorders that present with sclerodermoid features but are unrelated to scleromyxoedema. Scleromyxoedema is also distinct from generalized myxoedema of thyroid disease.

**Epidemiology**

Scleromyxoedema is a rare disease that usually affects middle-aged adults between the ages of 30 and 80 years, with no race or sex predominance. In a multicentre, retrospective study of 30 patients with scleromyxoedema, the mean age of affected patients was 59 years. This illness is extremely rare or almost absent in infants and young children.

**Pathogenesis**

The pathogenesis of scleromyxoedema is unknown. The significance of the associated monoclonal gammopathy and the underlying plasma cell clone is debated. The main hypothesis is that circulating cytokines, such as interleukin (IL)-1, tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta, known to stimulate glycosaminoglycan synthesis and fibroblast proliferation in the skin, may play a role.

A promoting role of TGF-beta has also been identified in case series by analysis of RNA in involved skin tissue. New insights were added by a study in which abnormally high secretion of IL-4, a profibrotic cytokine, was found in serum from scleromyxoedema patients, suggesting a chronic Th2-skewed T cell response against an unknown target antigen. The same study also found that both CD4+ and CD8+ T cells from patients with scleromyxoedema present a profound deficiency (even after stimulation) of the production of interferon-gamma and IL-17 compared to healthy donor control cells. The role of interferon-gamma in scleromyxoedema could be related to the lack of its inhibitory effect on both proliferation and extracellular matrix production by fibroblasts.

Clinical remission of scleromyxoedema following autologous stem cell transplantation suggests that the bone marrow may be a source of these circulating factors.

Many authors have also suggested that paraproteins themselves may be pathogenic, acting as autoantibodies that stimulate fibroblasts to proliferate and overproduce mucin. However, there are data conflicting with this theory. Although serum isolated from patients with scleromyxoedema has enhanced fibroblast proliferation in some in vitro studies, one of these studies also found that purified immunoglobulin from the serum did not stimulate fibroblast growth. In addition, a study in which serum from a patient with scleromyxoedema was found to increase production of hyaluronic acid (a component of mucin) and prostaglandin E by fibroblast cultures did not find a stimulatory effect of the serum on fibroblast proliferation. Moreover, paraprotein levels usually do not correlate with the severity of disease, disease progression or the response to treatment. Only on an anecdotal basis, has the complete resolution of skin lesions coincided with the normalization of the bone marrow and the disappearance of the paraprotein.

Additional theories on the pathogenesis of scleromyxoedema have been proposed. It has been suggested that an intrinsic abnormality of scleromyxoedema fibroblasts may result in increased glycosaminoglycan synthesis. In addition, case reports documenting the development of scleromyxoedema following a cutaneous, granulomatous reaction after intradermal hyaluronic gel injections or after breast silicone implantation may suggest a type of autoimmune syndrome induced by adjuvants.

**Clinical findings**

The clinical manifestations of scleromyxoedema include both cutaneous and extracutaneous features.

**Cutaneous manifestations**

The characteristic skin finding in scleromyxoedema is a widespread eruption of 2-3 mm, firm, waxy, closely spaced, dome-shaped or flat-topped papules involving the hands, forearms, head, neck, upper trunk and thighs. Papules are often arranged in a strikingly linear array, and the surrounding skin is shiny and indurate (sclerodermoid) in appearance. Rarely, nontender subcutaneous nodules are present. The glabella is typically involved with deep, longitudinal furrows that produce the characteristic leonine face. Deep furrowing also is typically evident on the trunk or limbs associated with redundant skin folds (known as "Shar-Pei sign"). Erythema, oedema and a brownish discoloration may be seen in the involved areas; pruritus is not uncommon.

Eyebrow, axillary and pubic hair may be sparse in patients with scleromyxoedema. The mucous membranes are spared. As the condition progresses, erythematous and infiltrated plaques may appear with skin stiffening, sclerodactyly and decreased motility of the mouth and joints. On the proximal interphalangeal joints, a central depression surrounded by an elevated rim (due to skin thickening) can be present and is referred to as the 'doughnut sign'. Unlike scleroderma, telangiectasias and calcinosis are absent. Although rare, the Raynaud phenomenon occurs, and when associated with sclerodactyly and decreased motility can pose a mimic of SSC, demanding careful further diagnostic measures.

**Extracutaneous manifestations**

Patients with scleromyxoedema can have a number of internal implications, including neurological, rheumatological, cardiovascular, gastrointestinal, pulmonary and renal manifestations. In a multicentre, retrospective study...
of 30 patients with scleromyxoedema, the most common extracutaneous manifestations were neurological abnormalities (30%), rheumatological abnormalities (25%) and cardiac abnormalities (22%).

Neurological manifestations

Neurological complications may involve the peripheral nervous system (e.g. carpal tunnel syndrome or peripheral sensory and motor neuropathy) or the central nervous system (e.g. memory loss, vertigo, gait problems, stroke, seizures, psychosis or ‘dermato-neuro syndrome’). Carpal tunnel syndrome is thought to be due to either deposition of glycosaminoglycans in the carpal tunnel or to a direct toxic effect in the median nerve. The dermato-neuro syndrome is an occasionally lethal, acute, neurological complication characterized by fever, confusion, dysarthria, lethargy, convulsions and coma. The dermato-neuro syndrome is often preceded by flu-like symptoms. In the French series, 18% of patients had dermato-neuro syndrome.

Rheumatological manifestations

Rheumatological manifestations are characterized by arthralgias or arthritis of the peripheral joints, especially of the hands, with noninflammatory synovial fluids. A severe, destructive, polyarthritis resembling rheumatoid arthritis also has been reported. Proximal or generalized weakness due to inflammatory myopathy and fibromyalgia is common and usually occurs several months or years after the onset of skin involvement. In these patients, muscle biopsy reveals a necrotizing and vacuolar myopathy; interstitial inflammatory infiltrates are found uncommonly and may cause confusion with polymyositis. A few cases of true dermatomyositis have been described in association with scleromyxoedema. Spontaneous or interferon alfa-induced rhabdomyolysis is an additional rare finding.

Cardiovascular manifestations

Cardiovascular abnormalities with congestive heart failure, myocardial ischaemia, heart block and pericardial effusion may occur. Valvular mucin deposition has been described in a case report.

Gastrointestinal manifestations

Dysphagia is the most common gastrointestinal manifestation and is related to oesophageal dysmotility mainly localized to the upper oesophagus. Dysphagia is most commonly found in patients with an associated myopathy. Nasal regurgitation may also occur.

Respiratory manifestations

Dyspnoea on exertion is the most common pulmonary finding, due to obstructive or restrictive pathology. In addition, hoarseness and aspiration may occur due to laryngeal involvement with decreased epiglottis and vocal cord mobility.

Renal manifestations

Involvement of the kidney, characterized by a scleroderma renal crisis-like acute renal failure, is a rare event.

Ocular manifestations

Infrequently, corneal opacities and ectropion are seen. The pathogenesis of the extracutaneous manifestations of scleromyxoedema is unclear. It has been suggested that mucin deposition in various organs may be the cause, although mucin is not consistently found on autopsy in fatal cases. In dermato-neuro syndrome, brain autopsy has not been contributory, and the pathogenic basis of the encephalopathy remains obscure. It has been proposed that an increased blood viscosity with impaired microcirculation due to paraproteinaemia may result in encephalopathy. A pathogenic role for immunoglobulin G (IgG) crossing a damaged blood–brain barrier, mediated by increased IL-6 production, has also been suggested.

Associated disorders

Scleromyxoedema is usually associated with monoclonal gammopathy. The monoclonal protein is most commonly IgG-lambda. However, less frequently, a different monoclonal protein type is present. Patients with scleromyxoedema in the absence of monoclonal gammopathy are considered to have an atypical form of the disease. A mild plasmacytosis may be present in the bone marrow of patients with scleromyxoedema. However, the disease is estimated to progress to multiple myeloma in less than 10% of cases, similar to monoclonal gammopathy of undetermined significance. Anecdotal associations with haematological malignancies (such as Hodgkin and non-Hodgkin lymphomas, Waldenström macroglobulinaemia, lymphoid leukaemia and myelomonocytic leukaemia) or visceral carcinomas have been reported. Although treatment of the primary cancer may result in the regression of the skin lesions, no clear association with any specific neoplasm has been identified. Most haemolymphoproliferative malignancies in
these patients are iatrogenic and associated with the use of melphalan treatment.27

Clinical course

Scleromyxoedema follows a chronic, progressive and sometimes unpredictable course. Depending on the rapidity of onset and the degree of involvement, patients may be either initially asymptomatic or may notice that skin becomes thick and hard and that the face shows a diffuse induration and coarsening in the forehead lines and lateral portions of the chin. As the disease progresses (usually over the course of years and, occasionally, over the course of several months), a diffuse, sclerodermoid induration with overlying papules, sclerodactyly and decreased motility of the mouth and joints occurs. Spontaneous resolution only very rarely occurs; at least one case of apparent spontaneous resolution has been reported.38 Systemic consequences of scleromyxoedema may result in death.1,32 In a case series in which follow-up was available for 21 patients with scleromyxoedema (mean follow-up time: 33.5 months, range: 2 months to 11 years), at the end of follow-up, five patients (23.8%) died, whereas 12 patients were alive with disease and four patients were alive without disease.1 Death was caused by extracutaneous complications of scleromyxoedema, including dermatoneuro syndrome (two patients) and myocardial insufficiency due to endocardial mucin deposition (one patient) or by an associated myeloid leukaemia (one patient) or Hodgkin lymphoma (one patient). A better prognosis was reported in a French study in which the overall survival of all 33 patients with scleromyxoedema was 97% at 3 years.5 Death also may occur as an adverse effect of treatment. In particular, treatment with melphalan has been associated with death from complications of sepsis and hematological malignancies.27 In the French study, one patient died of severe sepsis and specific heart involvement following chemotherapy treatment with bortezomib, melphalan and dexamethasone.5

Histopathology

Scleromyxoedema is characterized by a triad of microscopic features that includes39,40:

- A diffuse deposit of mucin composed primarily of hyaluronic acid in the upper and mid-reticular dermis; the presence of mucin can be confirmed with an Alcian blue stain (pH 2.5) or a colloidal iron stain and hyaluronidase digestion.
- An increase in collagen deposition.
- A marked proliferation of irregularly arranged fibroblasts.

The epidermis may be normal or thinned by the presence of the underlying mucin and fibrosis; the hair follicles may be atrophic, and a slight perivascular, superficial, lymphoplasmacytic infiltrate is often present. Sweat gland proliferations are found occasionally.31 The elastic fibres are fragmented and decreased in number, explaining the clinical presentation of redundant skin folds on a sclerodermoid background (‘shar pei sign’).42 Figure 1 shows an anonymized example of a scleromyxoedema face.

An interstitial, granuloma annulare-like pattern has been described in cutaneous biopsy specimens from patients with scleromyxoedema, occurring in approximately 25% of the specimens.43,44 This histological pattern is characterized by a diffuse, interstitial proliferation of blue-grey histiocytes (CD68+ and CD163+), giant cells and lymphocytes within the superficial and mid-dermal dermis, forming loose granulomas among collagen fibres and mucin deposits.

Histological specimens from extracutaneous sites may demonstrate mucin deposition among myocardial cells and in the walls of myocardial blood vessels as well as in the interstitium of the kidney, lungs, pancreas, adrenal glands and nerves.25,33 Lymph node involvement with infiltration by numerous fibroblasts surrounded by mucin and collagen deposits has been observed.45 Mucin has not been found in brain autopsies of patients who died of dermatoneuro syndrome.

Diagnosis

The diagnosis of scleromyxoedema is based upon the recognition of the following clinicopathological criteria:

- Diffuse/generalized, papular and sclerodermoid eruption.
- Microscopic triad, including mucin deposition, fibrosis, and fibroblast proliferation or, less frequently, an interstitial granulomatous-like pattern.
- Monoclonal gammopathy.

FIGURE 1 Scleromyxoedema face.
Atypical forms of scleromyxoedema include scleromyxoedema in the absence of monoclonal gammopathy or scleromyxoedema demonstrating an interstitial granulomatous-like pattern on histopathology.

Skin biopsy

Skin biopsy is the mainstay for diagnosis and should be performed on a group of papules with underlying thickening. Key findings include mucin deposition, fibrosis and fibroblast proliferation.

Immunofluorescence studies are not contributory to the diagnosis of scleromyxoedema and are usually negative. Anecdotally, scantly granular IgG along the epidermal basement membrane and IgG and C1q focally along the connective tissue fibres in the dermis of clinically involved skin have been detected.

Laboratory tests

The workup of patients with suspected scleromyxoedema should include the following laboratory studies to determine whether the diagnostic criteria are met:

- Serum protein immunoelectrophoresis, immunofixation and serum-free light chain assay to evaluate for monoclonal gammopathy.
- Thyroid studies to rule out myxoedema of thyroid disease.
- Serum protein immunofixation generally reveals the presence of a monoclonal protein, most commonly IgG-lambda type. Thyroid function test results are normal.

Additional tests

There is little value in imaging studies for the diagnosis of scleromyxoedema, although high-resolution cutaneous ultrasonography may become a useful diagnostic and disease activity monitoring tool for skin thickening.

Dermoscopy is nonspecific, showing rice grain-like structures corresponding to papules. Reflectance confocal microscopy features include dermal stellate cells, bright fibres and dark areas, corresponding to the classical triad of fibroblast proliferation, increased collagen deposition and mucin deposits respectively.

Although not necessary for diagnosis, nail fold videocapillaroscopy is normal or nonspecific in scleromyxoedema. This differs from systemic scleroderma, in which megacapillaries and decreased capillary density are characteristic features.

In patients who exhibit symptoms suggestive of extracutaneous disease, the corresponding internal organs should be evaluated. As examples, oesophageal manometry can be useful for evaluating patients with dysphagia, and pulmonary function studies, including spirometry for forced vital capacity and quantification of diffusing capacity for carbon monoxide, are appropriate for patients with dyspnoea. In dermatoneuro syndrome, lumbar puncture and magnetic resonance imaging typically reveal normal findings; however, electroencephalogram results may be consistent with toxic or metabolic encephalopathy.

Differential diagnosis

The major disorders in the differential diagnosis of scleromyxoedema are scleroderma (systemic sclerosis) and scleroedema and generalized myxoedema. Other disorders characterized by sclerodermoid skin changes may also enter the differential diagnosis.

Systemic sclerosis

Characteristic cutaneous findings of systemic sclerosis include skin thickening or hardening that begins on the fingers, hands or face with centripetal extension in the absence of papules. Raynaud phenomenon is present in more than 90% of patients and antecedes the sclerosis of fingers. Associated cutaneous findings include telangiectasia, digital ischemic ulcers and calcinosis. Nailfold capillaroscopy is useful for early diagnosis of systemic sclerosis, showing dilated and giant capillaries, haemorrhages, disorganized vascular arrays, ramified/bushy capillaries and capillary losses. Systemic sclerosis is associated with specific autoantibody profiles, including antitopoisomerase-1 (anti-Scl70) or anticientromere antibody (for details, please refer to Part I of the Sclerosing Diseases Consensus Statement).

Although patients with scleromyxoedema may have symptoms that mimic scleroderma, such as sclerodactyly, the Raynaud phenomenon (rarely) and oesophageal dysmotility, clinical and laboratory features distinguish the two diseases. The presence of diffuse, waxy papules in linear arrays and in a characteristic distribution that includes the glabella and posterior auricular area, the involvement of the middle portion of the back (always spared in scleroderma), and the presence of an IgG monoclonal gammopathy all favour a diagnosis of scleromyxoedema.

Scleroedema

Scleroedema (also known as scleroedema adultorum of Buschke) is characterized by a symmetrical, nonpitting induration of the skin that typically begins on the neck and later spreads to the shoulders and upper part of the trunk with occasional erythema. Scleroedema is typically associated with a history of an antecedent upper respiratory infection, diabetes mellitus or blood dyscrasia. The histological findings of scleromyxoedema and scleroedema differ; the fibroblast proliferation that is evident...
in histological specimens of scleromyxoedema is absent in scleromedema. 51

Generalized myxoedema

Generalized myxoedema is a manifestation of severe hypothyroidism in which mucin is deposited in the dermis, leading to waxiness of the skin. The initial symptoms are subtle and include mental and physical sluggishness, weight gain, constipation, leg cramps, loss of appetite and cold intolerance. The face has a dull expression with oedematous eyelids, broad nose, swollen lips and macroglossia. The skin is pale, cool, waxy and dry with absence of sweating, but the typical papular eruption of scleromyxoedema is missing. A yellowish discoloration of the palms and soles due to carotenemia may appear. Hair and nails are dry and brittle, and a diffuse non-scarring alopecia of the scalp and the lateral third of the eyebrows is common. The serum thyroid-stimulating hormone (TSH) is elevated with low levels of circulating T4. Histopathologically, mucin deposits (mainly perivascular and perifollicular) splay collagen bundles and may extend into the subcutaneous fat, but fibroblasts are not increased in number.

Importantly, scleromyxoedema should be differentiated from the localized variants of lichen myxoedematous. In the past, the terms ‘papular mucinosis’, ‘lichen myxedematous’ and ‘scleromyxiedema’ were often used indiscriminately. Although scleromyxoedema and the localized type of lichen myxoedematous (including subtypes such as acral persistent papular mucinosis, discrete lichen myxoedematous, papular mucinosis of infancy and nodular lichen myxoedematous) belong to the same disease spectrum, it is important to make a distinction between the two disorders because of differences in prognosis and the approach to therapy.2,5 Historically, most patients reported in the literature to have lichen myxoedematous or papular mucinosis without specification of the disease subtype appear to have had scleromyxoedema with monoclonal gammopathy. Occasionally, patients have overlapping or atypical features and fall in between scleromyxoedema and localized lichen myxoedematous. 3

Treatment

Although treatment of scleromyxoedema is recommended to minimize risk for the development of complications, a paucity of high-quality studies on the efficacy of treatments for scleromyxoedema and an incomplete understanding of the pathogenesis of the disorder have prevented the development of definitive guidelines on the best approach to treatment. No randomized trials have evaluated therapies for scleromyxoedema, and data are primarily limited to case reports and case series due to the rarity of the disease. No specific treatment appears to be uniformly effective or curative, and the relative efficacies of the treatments that have been utilized remain unclear.

As a consequence of the limited data on therapies for scleromyxoedema, opinions vary on the preferred approach to treatment. In all cases, consideration of the risk–benefit ratio of treatment is important for selecting an appropriate therapeutic regimen; both scleromyxoedema and its therapies may induce life-threatening adverse effects.

Complete resolution of the manifestations of scleromyxoedema is the goal of treatment but is not always feasible. Marked improvement in papules and skin thickening is generally considered a successful response of skin disease.52 Consideration of patient characteristics, patient preferences, clinician experience and treatment accessibility may support the approach to treatment. Of note, successful treatment of scleromyxoedema does not appear to require the resolution of the associated paraproteinaemia.

Preferred initial therapy

Systemic therapy is the treatment method of choice for patients with scleromyxoedema (Figure 2). Intravenous immunoglobulin (IVIG) is our first choice for therapy, based upon multiple case reports and case series that support its efficacy and the generally well-tolerated nature of this immunomodulatory treatment.5,52,53 For those patients who cannot receive IVIG, systemic glucocorticoids and immunomodulatory drugs (thalidomide or lenalidomide) are our preferred initial systemic therapies.

In the past, melphalan, a chemotherapeutic agent given with the intent to treat the associated plasma cell dyscrasia, was often considered first-line treatment for scleromyxoedema. However, concerns regarding serious adverse effects, including haematological malignancies and opportunistic infections, contributed to a desire for other less toxic first-line therapies for scleromyxoedema.

**Intravenous immunoglobulin (IVIG)**

The mechanism by which IVIG improves scleromyxoedema is unclear. Suggested mechanisms focus on the immunomodulatory effects of IVIG, including neutralization of circulating autoantibodies by anti-idiotypic antibodies, functional blockade of fragment crystallizable (Fc) receptors on macrophages and inhibition of fibrosis via modulation of the production of cytokines and cytokine antagonists.54,55

**Administration.** IVIG is usually administered at the dose of 2 g/kg per month divided over 2–4 consecutive days per cycle according to the preparation and concentration of IVIG. Improvement in skin and extracutaneous symptoms, especially rheumatological symptoms, often is evident after the first one or two cycles of IVIG.1,5,6,57 In our experience, almost all patients exhibit at least partial improvement within 4–6 cycles. Patients with an unsatisfactory response to IVIG after six cycles are typically transitioned to other therapies.
Lower doses of IVIG may also be effective. A patient with skin-limited disease who had failed to respond to systemic glucocorticoids, extracorporeal photopheresis and interferon had a reduction in clinical findings within two cycles of IVIG given at a dose of 0.5 g/kg over five days at 4-week intervals.56

Although remissions persisting for a few months to three years after cessation of IVIG infusions have been reported, the response to IVIG is usually transient.28,57,58 Maintenance IVIG cycles every 6–8 weeks are generally required to maintain remission.57 Usually, IVIG is administered over 2–4 days at a dose of 2 g/kg of IVIG every six weeks or 1.5 g/kg of IVIG every four weeks.

Drawbacks of IVIG treatment are its high cost and the time-consuming administration. The use of more concentrated IVIG, reducing the time of administration to two days, has improved the management of the disease. Possible adverse effects are skin flushes, vesicular or bullous dermatitis of the hands, arthralgias, myalgias, fever, headache, aseptic meningitis, thoracic or abdominal pain, nausea and tachycardia. Myocardial ischaemia and death secondary to suspected myocardial infarction have been reported in scleromyxoedema patients with known cardiac risk factors during treatment with IVIG.1,59 However, the adverse effects experienced by patients receiving IVIG for scleromyxoedema generally have been mild and self-limited.60

**Efficacy.** Data on the efficacy and safety of IVIG are primarily limited to case reports and case series; no randomized trials have been performed.1,5,6,28 Examples of published reports that have offered support for the efficacy of IVIG for this disease include:

- In a retrospective study, 13 of 31 patients (42%) with scleromyxoedema (without features of dermat-neuro syndrome or mucinous cardiac involvement) treated with IVIG (2 g/kg monthly for the first six months) as a first-line therapy achieved a complete clinical response. Patients were treated with IVIG for a median of 16 months.

- In a review of eight adults with scleromyxoedema who were treated with monthly cycles of IVIG (2 g/kg per cycle divided over 2–5 days), all achieved a response (2—complete response and 6—partial response) after up to six cycles of IVIG.28 Treatment was followed by maintenance therapy every 6–12 weeks as needed.

- In a multicentre, retrospective study of 30 patients with scleromyxoedema, three of the six patients treated with IVIG (2 g/kg per monthly cycle) achieved complete clinical remissions.5 The three remaining patients achieved partial responses.

In the first study, a complete clinical response was defined as complete clinical improvement from baseline. In the latter two studies, complete responses were defined as an absence of systemic symptoms or skin findings of scleromyxoedema, and partial responses consisted of a decrease in skin changes and improvement in systemic symptoms. In these and other reports, responders to IVIG have included both patients who received IVIG as initial treatment and patients who had previously failed other therapies.1,5,28,57,61
Failure of initial therapy

In the few cases in which treatment with IVIG is not an option or yields an insufficient response, we institute other therapies. Systemic glucocorticoids and thalidomide are our preferred next-line treatments. Systemic glucocorticoids and thalidomide can be given alone. More often, we add one of these agents to IVIG therapy because of the favourable results we have observed with combination therapy.

Selection between systemic glucocorticoids and thalidomide is based upon consideration of factors such as patient comorbidities, tolerability, drug availability and clinician comfort. Most often, we use systemic glucocorticoids first; only if the response is insufficient do we begin thalidomide, as adverse events under steroids are usually better controlled than those under thalidomide (e.g. irreversible peripheral polyneuropathy).

Patients with severe disease who cannot be successfully managed with IVIG, thalidomide, and/or systemic glucocorticoids are candidates for trials of more aggressive interventions, where such trials are available.

Systemic glucocorticoids

Systemic glucocorticoids have been used for scleromyxoedema as monotherapy or in conjunction with chemotherapeutic agents. It is postulated that benefit from systemic glucocorticoids may result from immunosuppressive and antifibroblast effects of these agents.

Administration. Our preferred regimen for systemic glucocorticoid therapy is prednisone (0.5–1 mg/kg per day) until the desired therapeutic effect is reached. Responses usually occur within four weeks. Then, we begin to slowly taper the glucocorticoid dose to the lowest dose necessary to maintain the response to treatment. If patients failed to respond within 4–6 weeks, we consider treatment ineffective and typically transition to thalidomide.

Efficacy. Data on the efficacy of systemic glucocorticoids in scleromyxoedema are limited to case reports. Prednisone (0.5–1 mg/kg per day), prednisolone (0.3–0.5 mg/kg per day) and oral high-dose dexamethasone (40 mg once daily for four days per week during three consecutive weeks each month) have been associated with improvement in cutaneous manifestations of scleromyxoedema in individual patients. The associated paraproteinaemia may or may not improve in patients in whom systemic glucocorticoid therapy induces remission of scleromyxoedema. Failure of systemic glucocorticoid therapy to improve scleromyxoedema has also been reported.

Immunomodulatory drugs (thalidomide or lenalidomide)

The mechanism of action of thalidomide in scleromyxoedema is unknown. Immunomodulatory effects on proinflammatory and profibrotic cytokines and antiangiogenic properties may contribute to inhibition of fibrosis.

Lenalidomide, a thalidomide derivative with a more favourable adverse effect profile, may be a reasonable alternative to thalidomide. Disadvantages of lenalidomide compared with thalidomide include higher cost and less data on the efficacy of this therapy.

Administration. Treatment with thalidomide should begin at a dose of 50–100 mg per day, then increase slowly up to 150–400 mg per day according to clinical response and tolerance. Clinical improvement is expected within 2–3 months, and a change in therapy is appropriate for patients who exhibit no improvement within this period. Once a satisfactory response to thalidomide is achieved, the lowest effective dose is used for maintenance therapy. Teratogenicity and peripheral neuropathy are adverse effects of thalidomide that can limit the use of this therapy and other adverse effects include drowsiness, constipation, thrombosis and leukopenia. Patients should be monitored for the development of peripheral neuropathy during treatment. Lenalidomide, a haematological agent, is usually used at a dose of 10–25 mg per day for three weeks per month, starting with the lower dose. Once response is achieved, the lenalidomide dose can be reduced to the lowest dose effective for maintaining improvement.

Examples of potential adverse effects of lenalidomide include teratogenicity, thrombocytopenia, neutropenia and thrombosis.

Efficacy. Multiple case reports have documented improvement in the cutaneous manifestations of scleromyxoedema following treatment with thalidomide. Improvement in systemic manifestations and serum paraprotein levels have also been reported in some patients. Thalidomide may be a useful adjunct to IVIG therapy; the addition of thalidomide to IVIG appeared to be useful for decreasing the frequency of IVIG treatment in a case report.

A few case reports and series have documented the use of lenalidomide. In a retrospective study, treatment of three patients with IVIG-refractory scleromyxoedema with lenalidomide, dexamethasone and IVIG was associated with partial clinical responses and complete haematological responses in all patients. In case reports, lenalidomide (25 mg per day for three weeks per month) appeared beneficial when used in combination with IVIG in one patient but failed to induce clinical improvement when used in combination with dexamethasone in another patient.

Severe and refractory disease

Patients who fail to achieve sufficient improvement with the therapies above may benefit from interventions aimed at treating the associated plasma cell dyscrasias.

Examples of therapeutic options include bortezomib, a proteasome inhibitor, with dexamethasone, autologous stem cell transplantation and melphalan. Data are limited
on the efficacy of these therapies for cutaneous and extracutaneous manifestations of scleromyxoedema. In addition, the response to these treatments is variable and relapse may occur. Thus, the risks associated with these therapies must be considered carefully prior to treatment.

Our typical approach to severe disease that has failed to respond to IVIG, systemic glucocorticoids and immunomodulatory drugs starts with bortezomib in addition to dexamethasone therapy. Poor responders are candidates for autologous stem cell transplantation. We generally avoid melphalan because of concern for serious haematological toxicity, including malignancy.

**Bortezomib and dexamethasone**
Combination therapy with bortezomib and dexamethasone has been associated with rapid improvement in cutaneous manifestations and constitutional symptoms of scleromyxoedema in case reports, including a patient who relapsed after autologous stem cell transplantation. A successful response was also observed in a patient treated with bortezomib and dexamethasone in combination with thalidomide. Our typical regimen involves bortezomib given at a dose of 1.3 mg/m² (maximum of 2 mg per dose) on days 1, 8, 15 and 22. Dexamethasone (40 mg per dose) is given on days 1, 8, 15 and 22. A total of six cycles are given over a period of six months. In very refractory cases, thalidomide may be added, given at a dose of 100 mg per day for the first 14 days followed by 200 mg per day for the next seven days, similar to a protocol used for myeloma.

**Autologous stem cell transplantation**
Multiple cases of scleromyxoedema treated with autologous stem cell transplantation have been reported since the initial report of a complete remission in 2001. In a review of 17 reported cases of scleromyxoedema treated with autologous stem cell transplantation published between 2001 and 2011, complete remissions (resolution of all clinical symptoms, skin abnormality and serum paraprotein) were attained by 10 patients (59%) and partial remissions were attained by five patients (29%). However, only two of the complete responders remained in remission after follow-up periods ranging between 14 and ≥60 months. Allogeneic haematopoietic cell transplant has also been tried with success in a patient with refractory disease.

**Melphalan**
Although melphalan was often considered a first-line treatment for scleromyxoedema in the past, the potential for drug-related serious adverse events, and the efficacy achieved with the aforementioned drugs, limits the use of this agent. A review of 17 patients who received melphalan for scleromyxoedema (1–4 mg per day or cyclic therapy) at a single medical centre found that although 12 patients had improvement of skin disease with therapy, improvement was temporary in eight patients and nine patients died of haematological malignancy or septic complications that were considered related to therapy.

**Dermato-neuro syndrome**
The approach to patients with dermato-neuro syndrome is not standardized, and various treatments have not seemed to yield benefit in case reports. Examples include IVIG, systemic glucocorticoids plus plasmapheresis or IVIG, systemic glucocorticoids plus cyclophosphamide and plasmapheresis, melphalan plus IVIG and bortezomib plus dexamethasone. Spontaneous improvement also has been reported.

Our typical initial approach consists of IVIG (2 g per kg per month) with dexamethasone pulse therapy (intravenous dexamethasone [100 mg per day] given for three consecutive days per month). This may be followed by the addition of plasmapheresis (every other day for 10 days) for patients who do not improve within two cycles of IVIG and dexamethasone therapy (Figure 3).

**Other therapies**
Case reports have documented clinical improvement in patients treated with topical betamethasone and topical dimethyl sulfoxide, topical and intranasal corticosteroid therapy, oral isotretinoin, acitretin, interferon-alfa, hydroxychloroquine, cyclosporine, and chemotherapeutic agents, including cyclophosphamide, methotrexate, chlorambucil, and 2-chlorodesoxyadenosine. The efficacies of these agents for scleromyxoedema remain to be confirmed. Of note, treatment with interferon-alfa was associated with worsening of symptoms in a woman with localized lichen myxoedematosus. Some case reports have suggested that JAK inhibition and dupilumab may also be used.

Ultraviolet A1 (UVA1) or psoralen plus ultraviolet A (PUVA) phototherapy, Grenz ray and total skin

![FIGURE 3](image-url)
electron beam therapy have also been reported to improve cutaneous manifestations of scleromyxoedema in case reports. The therapeutic mechanisms of the different phototherapy modalities with their antiinflammatory components in skin conditions including scleromyxoedema have been recently reviewed. These therapies do not have an impact on paraproteinaemia and systemic involvement. Of note, accidental excessive exposure to ultraviolet B (UVB) has appeared to exacerbate the disease in one patient.

Tumour necrosis factor (TNF)-alpha inhibitors may not be useful. TNF-alpha has been suggested as a profibrotic cytokine that may be implicated in the pathogenesis of scleromyxoedema, and a patient in whom IVIG lost efficacy failed to respond to infliximab.

Cosmetic interventions
Case reports suggest that facial disfigurement can be treated with dermabrasion plus surgery or carbon dioxide laser with good cosmetic results. These procedures of course do not affect systemic manifestations of scleromyxoedema.

Prognosis and follow-up
Scleromyxoedema is a disease with an unpredictable but usually progressive and disabling course in the absence of successful treatment. Even when therapy is successful, long-term maintenance therapy usually is required since relapse commonly occurs upon the discontinuation of treatment. Death may result from complications of extracutaneous involvement or adverse effects of therapy. Because of the various cutaneous and extracutaneous manifestations of scleromyxoedema, a multispecialty team often is needed for the optimal management of these patients. Depending on the manifestations present, dermatologists, haematologists, cardiologists, pulmonologists, gastroenterologists, hand surgeons and other specialists can be valuable for managing affected patients.

The unpredictable course of scleromyxoedema, the variable response to treatment and the common occurrence of relapse demand close, long-term follow-up of these patients. We usually reassess patients once per month with a full skin examination, review of systems and re-evaluation of the therapeutic regimen. Serological studies, including assessment of the status of the associated monoclonal gammopathy, are not useful for monitoring disease activity.

Patients should be cautioned that development of neurological symptoms (e.g. dysarthria) and flu-like illness may be the initial signs of dermatomeuro syndrome. Patients with such symptoms should be admitted to the hospital for close observation, evaluation and eventually admission to the intensive care unit.

Follow-up data on patients treated for scleromyxoedema are limited, but relapse after treatment appears to be common. Most patients treated with IVIG require continued therapy to remain in remission. Frequent relapses have also been reported following autologous bone marrow transplantation and melphalan therapy. No treatment has been identified that definitively cures the disease.

Recommendations
- Scleromyxoedema is an uncommon, diffuse/generalized, papular and cutaneous eruption that usually occurs in association with monoclonal gammopathy and may have accompanying systemic features. The disorder typically affects adults. There is no sex predilection. The pathogenesis of scleromyxoedema is unknown, but circulating cytokines, such as IL-1, TNF-alpha, TGF-beta and IL-4, known to stimulate glycosaminoglycan synthesis and fibroblast proliferation in the skin, seem to play a role.
- The cutaneous manifestations of scleromyxoedema consist of widespread, waxy papules and indurated plaques. Progressive cutaneous involvement can lead to decreased motility of the mouth and joints. Extracutaneous involvement in scleromyxoedema can present with a variety of manifestations. Neurological, musculoskeletal, cardiac, gastrointestinal, respiratory or renal abnormalities may develop.
- The clinical course of scleromyxoedema is chronic and progressive. Cutaneous and extracutaneous involvement can lead to significant morbidity. Death may result from complications related to extracutaneous involvement or adverse effects of therapy.
- The diagnosis of scleromyxoedema is based upon recognition of consistent clinical, pathological and laboratory findings. The presence of the following features is supportive of the diagnosis:
  1. Diffuse/generalized, papular and scleroderma-like eruption.
  2. Microscopic triad, including mucin deposition, fibrosis and fibroblast proliferation, or, less frequently, an interstitial granulomatous-like pattern.
  3. Monoclonal gammopathy.
- There is a paucity of data on the treatment options for scleromyxoedema. The available data consist primarily of case reports and case series. Thus, there are no definitive consensus on the best approach to treatment.
- Patients with scleromyxoedema generally require systemic therapy. We suggest IVIG as initial treatment (Grade 2C). Systemic glucocorticoids and immunomodulatory drugs (thalidomide or lenalidomide) are alternative treatment options that may also be used in conjunction with IVIG therapy.
- Patients who fail to respond to IVIG, systemic glucocorticoids or immunomodulatory drugs may benefit from other therapies. Examples of treatment options for severe and refractory disease include bortezomib plus dexamethasone, autologous stem cell transplantation and melphalan. The risk–benefit ratios of treatment must be carefully considered prior to therapy.
• Recurrence of scleromyxoedema is common after withdrawal of an effective therapy. Long-term maintenance treatment usually is required, and close clinical follow-up is necessary.

**SCLEROEDEMA**

**Epidemiology and pathogenesis**

Scleroedema (of Buschke) is a rare scleromucinous connective tissue disease. Scleroedema occurs in individuals of all ages and ethnicities, and contradictory to Buschke's original description as 'scleredema adultorum', more than 50% of patients are aged under 20 years. The exact prevalence and incidence of scleroedema are not known. Prospective studies showed prevalence of 2.5–14.0% in patients with diabetes mellitus, suggesting that scleroedema is an underrecognized disease.

Three types of scleroedema can be distinguished, according to their association with preceding or underlying conditions:

- **Type 1 scleroedema** (the classic 'Buschke' type, 55% of cases) usually follows a febrile infection, especially streptococcal or viral respiratory tract infection, and affects mainly children and women. Recently, one case has been reported on scleroedema after developing SARS-CoV2 infection.
- **Type 2 scleroedema** is associated with haematological diseases like paraproteinaemia including monoclonal gammopathy, multiple myeloma and amyloidosis. Haematological diseases often develop years after onset of scleroedema.
- **Type 3 scleroedema** was named 'scleredema diabeticorum' by Krakowski and colleagues, and manifests mostly in men with diabetes mellitus.

Scleroedema can be associated with several other systemic diseases like rheumatoid arthritis, ankylosing spondylitis, Sjögren's syndrome, dermatomyositis, hyperparathyroidism, hyperthyroidism, Waldenström's macroglobulinaemia, anaphylactoid purpura, primary biliary cirrhosis, IgA deficiency, human immunodeficiency virus infection, and pyoderma gangrenosum. Cases of concomitant neoplasms have been reported, such as malignant insulinoma, gall bladder carcinoma, carcinoid tumour, adenocorticotropic hormone-producing pituitary tumour and ovarian/breast carcinoma.

In type 1 and 2 scleroedema, women are affected almost twice as frequently as men. In contrast, in type 3 scleroedema, the male-to-female ratio is considered to be 10:1. Very little is known about pathophysiology of scleroedema. Excessive production of mucin (heavily glycosylated high-molecular weight proteins) and collagens by fibroblasts from the reticular dermis is characteristic of scleroedema. This may be provoked by diverse stimuli, including infections, inflammatory processes, hypoxia, microvascular damage, drugs, toxins, genetic factors and hyperinsulinism or chronic hyperglycaemia.

**Diagnostic procedures**

**Clinical presentation**

The clinical symptoms of scleroedema include cutaneous and extracutaneous findings, depending on the type of the disease. The mRSS (developed for systemic sclerosis) may be used to evaluate the severity of skin involvement and to document its activity.

Type 1 scleroedema starts suddenly 1–3 weeks after respiratory infection with fever and usually resolves in a few months. Types 2 and 3 are mostly slowly progress and persist for years. Cases with limited periorbital manifestation and one unusual case of unilateral scleroedema have been reported.

Extracutaneous involvement is possible in all three forms of scleroedema and include serositis, arthropathy, myositis, dysphagia, dysphonnia, parotitis, ophthalmoplegia or cardiomyopathy.

**Histopathology**

A deep skin biopsy that includes subcutaneous fat is required to confirm the diagnosis and to exclude other sclerosis-like disorders.

The following histopathological findings are characteristic for scleroedema:

- The epidermis is usually not involved.
- The dermis is up to four times thicker than normal, due to enlarged collagen bundles in deep reticular dermis with wide, clear, mucin-filled spaces between them. Mucin deposits represent non-sulphated acid mucopolysaccharides, mainly hyaluronic acid, stainable with Alcian blue dye, colloidal iron or toluidine blue. In cases of systemic disease, mucin deposits can also be found in muscles and heart. In some cases, multiple biopsies are required in order to detect mucin deposits within the dermis, and therefore, the absence of mucin deposits does not exclude the diagnosis of scleroedema.
no proliferation of fibroblast can be detected in dermis from skin biopsies in patients with sclerodema, in contrast to scleromyxoedema.

- The subcutaneous fat is sometimes replaced by collagen fibres.
- Skin appendages are usually preserved (unlike in systemic sclerosis). However, some authors have reported the loss of eccrine glands.

Laboratory parameters

Fasting glucose, HbA1c, leukocyte count (lymphocytes), serum protein electrophoresis, serum and urine immunofixation and AST throat cultures should be performed to screen for diabetes and monoclonal gammopathy. If paraproteinaemia becomes apparent, additional investigations should be discussed, including cytofluorometry analysis (for the detection of B-cell lymphoproliferation). Antinuclear antibody (ANA) testing is negative, in contrast to most cases with systemic sclerosis.

Imaging

A durometer or an ultrasonography measurement of skin thickness may be performed in order to evaluate the severity and to monitor the disease. Range of motion, especially within the shoulder girdle, is well suited to monitoring disease. In cases of systemic involvement, specific diagnostic examinations are required (e.g. pulmonary function tests, ultrasonography of internal organs, including the heart, liver or spleen, oesophageal manometry, radiography or ultrasonography of bones and joints). In cases of monoclonal gammopathy or clinical evidence of enlarged lymph nodes, chest and abdomino-pelvic computerized tomography scan, positron emission tomography scan, lumbar and dorsal magnetic resonance imaging and/or myelogram/osteomedullar biopsy are the methods of choice.

In summary, the diagnosis of sclerodema is made clinically, with the definitive diagnosis confirmed by histopathology. A typical woody thickening of the skin which starts on the neck or upper trunk and spares acral locations (hands are not involved), history of a preceding infection, underlying paraproteinaemia or diabetes and accumulation of mucopolysaccharides in the microscopic evaluation are the main diagnosis criteria of sclerodema.

Differential diagnoses

Typical symmetrical localisation of skin hardening and histological features like the characteristic thickness of the dermis with the accumulation of mucin distinguish sclerodema from other sclerotic disorders. Very rarely, a combination of sclerotic disorders in one patient is possible. Differential diagnoses are summarized in Table 1.

Treatment

The evidence for therapeutic effects in sclerodema is based on retrospective studies, case reports and case series. The lack of randomized controlled trials for sclerodema creates difficulty in concluding the best treatment regimens, optimum dose and long-term efficacy.

Therapy is needed in patients with reduced mobility, due to skin hardening or systemic involvement. In addition, appropriate treatment should be performed if an associated condition could be identified (infection in type 1 sclerodema, a lymphoproliferative disorder in type 2, or diabetes mellitus in type 3).

Physical therapy is recommended for all three types of sclerodema, in order to improve the mobility of patients. Escalation of therapy in resistant cases of sclerodema is possible through the use of phototherapy (PUVA, UVA1 and narrowband UVB) or drug treatment (Table 2). Table 2 summarizes the treatment options for sclerodema. The risk–benefit ratio must be analysed for each patient before initiating therapy. Further studies are needed to explore the evidence level of suggested treatments.

Clinical course and prognosis

Sclerodema leads to decreased quality of life and higher morbidity, but only in sporadic cases, and to increased mortality due to cardiac or lung involvement.

The efficacy of treatments for sclerodema can be assessed using the mRSS, Health Assessment Questionnaire (HAQ), the range of motion of involved joints and the Dermatology Life Quality Index (DLQI).

Type 1 sclerodema associated with a preceding infection is characterized by a good prognosis and even spontaneous resolution. The active phase lasts 2–8 weeks and is followed by a resolution in a couple of months to 2 years.

Type 2 sclerodema (which is associated with blood dyscrasia) should be carefully followed up. The prognosis is poor; the lesions are persistent with possible systemic involvement leading to life-threatening complications. In patients with or without identified lymphoproliferation, leukocyte count (lymphocytes), serum protein electrophoresis and serum and urine immunofixation, as well as a thorough physical examination for lymph node enlargement and/or hepato-splenomegaly, should be performed annually. If monoclonal gammopathy of unspecified significance is detected, the risk of multiple myeloma or another related malignancy is about 1% per year.

Type 3 (diabetic) sclerodema has a poor prognosis, with a chronic progressive course and systemic complications. It also requires follow-up of patients with monitoring of the metabolic state (fasting blood glucose, HbA1c, and body weight). Sleep apnoea syndrome is common, and specific diagnostic tests are necessary to confirm the disorder. With the advent of new antidiabetic drugs and the ability to rigorously regulate blood glucose levels, more frequent and...
Scleroedema after radiation treatment is possible. 158 Amyloidosis, however, may be a consequence of advanced lymphoproliferative disease as the underlying cause of type 2 scleroedema. Abbreviation: ANA, antinuclear antibodies.

Radiotherapy- induced eosinophilic fasciitis • Induration in areas corresponding to myxoedema • Clinical and serological thyroid function abnormalities

Systemic sclerosis • Skin thickening typically begins at the fingertips, progressing to involve the hands and feet (spared in scleroedema) • Raynaud’s phenomenon, abnormal nail fold capillaries and ANA (absent in scleroedema) • No mucin deposits

Scleromyxoedema • Induration of the skin progresses acrally and typically forms characteristic large folds or firm papules, often in linear order (unlike in scleroedema) • Systemic complications and the association with monoclonal gammopathy and mucin deposits are common in both diseases

Myxoedema • Clinical and serological thyroid function abnormalities

Eosinophilic fasciitis • Induration in areas corresponding to the anatomic localization of the fascia on the trunk and extremities (unlike in scleroedema) • Depression along the course of the superficial veins (Groove sign) • Eosinophilia (absent in scleroedema) • No mucin deposits 4

Cutaneous amyloidosis • Characteristic amyloid deposits found in the affected tissues when stained with Congo red dye 5

Lymphoedema • The removal or damage to lymph nodes is common in the medical history • Affects the extremities; is most strongly expressed acrally (unlike in scleroedema) • Keratinocyte hypoproliferation, condensed dermal collagen and mononuclear perivascular infiltrate (unlike in scleroedema) • No mucin deposits

Cardiac or renal oedema • Oedema is usually non-solid, ‘pitting’ and is likely to occur in acral locations (unlike in scleroedema) • Symptoms of heart or renal failure • Different histopathological features • No mucin deposits

Radiotherapy-induced skin thickening • Previous radiotherapy 2 • Lesions are usually limited to the exposed area • No mucin deposits

Graft-versus-host disease • History of haematopoietic cell transplantation • No mucin deposits

Table 1: Differential diagnoses of scleroedema.

<table>
<thead>
<tr>
<th>Differential diagnosis</th>
<th>Distinguishing features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic sclerosis</td>
<td>• Skin thickening typically begins at the fingertips, progressing to involve the hands and feet (spared in scleroedema) • Raynaud’s phenomenon, abnormal nail fold capillaries and ANA (absent in scleroedema) • No mucin deposits</td>
</tr>
<tr>
<td>Scleromyxoedema</td>
<td>• Induration of the skin progresses acrally and typically forms characteristic large folds or firm papules, often in linear order (unlike in scleroedema) • Systemic complications and the association with monoclonal gammopathy and mucin deposits are common in both diseases</td>
</tr>
<tr>
<td>Myxoedema</td>
<td>• Clinical and serological thyroid function abnormalities</td>
</tr>
<tr>
<td>Eosinophilic fasciitis</td>
<td>• Induration in areas corresponding to the anatomic localization of the fascia on the trunk and extremities (unlike in scleroedema) • Depression along the course of the superficial veins (Groove sign) • Eosinophilia (absent in scleroedema) • No mucin deposits 4</td>
</tr>
<tr>
<td>Cutaneous amyloidosis</td>
<td>• Characteristic amyloid deposits found in the affected tissues when stained with Congo red dye 5</td>
</tr>
<tr>
<td>Lymphoedema</td>
<td>• The removal or damage to lymph nodes is common in the medical history • Affects the extremities; is most strongly expressed acrally (unlike in scleroedema) • Keratinocyte hypoproliferation, condensed dermal collagen and mononuclear perivascular infiltrate (unlike in scleroedema) • No mucin deposits</td>
</tr>
<tr>
<td>Cardiac or renal oedema</td>
<td>• Oedema is usually non-solid, ‘pitting’ and is likely to occur in acral locations (unlike in scleroedema) • Symptoms of heart or renal failure • Different histopathological features • No mucin deposits</td>
</tr>
<tr>
<td>Radiotherapy-induced skin thickening</td>
<td>• Previous radiotherapy 2 • Lesions are usually limited to the exposed area • No mucin deposits</td>
</tr>
<tr>
<td>Graft-versus-host disease</td>
<td>• History of haematopoietic cell transplantation • No mucin deposits</td>
</tr>
</tbody>
</table>

Marked improvements have been seen in type 3 scleroedema. As diabetic scleroedema is under-recognized, there is a need for appropriate education.

Table 2: Treatment of scleroedema.

<table>
<thead>
<tr>
<th>Treatment indication</th>
<th>Therapeutic measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of the identified cause:</td>
<td></td>
</tr>
<tr>
<td>Type 1</td>
<td>• Antimicrobial agents, if indicated</td>
</tr>
<tr>
<td>Type 2</td>
<td>• Therapy of the identified lymphoproliferative disorder in consultation with a haematologist</td>
</tr>
<tr>
<td>Type 3</td>
<td>• Anti-diabetics, insulin (blood glucose self-monitoring)</td>
</tr>
<tr>
<td>Treatment for all three types of scleroedema</td>
<td>• Physical therapy 4</td>
</tr>
<tr>
<td>In cases with persistent skin hardening with reduced mobility or systemic involvement</td>
<td>• First line: medium-to-high-dose UVA1 or PUVA 5 • Second line: methotrexate (glucocorticoids, except for diabetic patients) • Advanced line: other treatments 5</td>
</tr>
</tbody>
</table>

*To increase the range of motion of involved joints and respiratory rehabilitation. 159
1 For more information, please refer to the Section I—Localized scleroderma.
2 If methotrexate fails or is contraindicated, based on a risk–benefit approach, the following alternative treatments can be proposed: glucocorticoids, systemic or intralesional, 160 cyclosporine, 161,162 prostaglandin E1, 163 intravenous immunoglobulins, 164,165 high-dose penicillin, 166 factor XIII infusion, 167 cyclophosphamide, 168 tranilast, 169 thalidomide, 170 radiotherapy, 171 extracorporeal shock wave therapy, 172 electron-beam radiotherapy 173 and extracorporeal photopheresis. 174

Abbreviation: ANA, antinuclear antibodies.

*The biopsy should be sufficiently deep to reach the fascia.

Amyloidosis, however, may be a consequence of advanced lymphoproliferative disease as the underlying cause of type 2 scleroedema.

Scleroedema after radiation treatment is possible. 158

Recommendations

The diagnosis of scleroedema is made clinically: a typical woody thickening of the skin which starts on the neck or upper trunk and spares acral locations (hands are not involved), history of a preceding infection, underlying paraproteinaemia or diabetes. A histopathological examination (mucin deposits in dermis) is performed to confirm a definitive diagnosis.

Scleroedema type 1 does not usually require treatment, as it is self-limited and usually resolves in a short period of time. If the patient wishes to have therapy, physical therapy (and sometimes also phototherapy) can be recommended.

If associated conditions are identified (infection in type 1 scleroedema, lymphoproliferative disorder in type 2 or diabetes mellitus in type 3), appropriate therapy should be performed.

If patient follow-up in persistent scleroedema is needed to screen for paraproteinaemia, systemic complications and co-morbidities; a follow-up every 3 months is recommended for patients with progressing disease, and a yearly follow-up is recommended for those with stable disease.

No specific therapy for scleroedema is available, although numerous methods have been proposed based...
on retrospective studies, case reports and case series (low
evidence). The recommended first-line treatment is phytotherapy. If this fails, methotrexate is recommended.
• Randomized controlled trials for sclerodema should be performed in the future to identify the best treatment
regimens, optimum dose and long-term efficacy of the therapy.

Methods

The current consensus statement on diagnosis and treatment of sclerosing diseases of the skin was developed through dis-
cussion with a panel of 30 international experts in dermatol-
yogy, rheumatology and related fields in an iterative process. Multiple rounds of emails were shared to gather individual
opinions and recommendations on the topic in question, allowing participants to review and revise their responses until a consensus was reached.

AFFILIATIONS

1Department of Dermatology, Medical University of Vienna, Vienna, Austria
2Department of Dermatology, Ordensklinikum Linz Elisabethinen, Linz, Austria
3Faculty of Medicine, Johannes Kepler University, Linz, Austria
4Department of Dermatology, Venerology and Allergology, HELIOS St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany
5Department of Dermatology and Venerology, University of Cologne, Cologne, Germany
6Vita Salute University IRCSS San Raffaele Hospital, Milan, Italy
7Center for Rheumatology, Royal Free and University College Medical School, London, UK
8Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Systémiques Rares de l’Île de France, APHP-CUP, Hôpital Cochin, Paris, France
9Institut Cochin, Université de Paris Cité, Paris, France
10Laboratories for Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine DiMII, University Medical School of Genoa, IRCCS San Martino Genoa, Genova, Italy
11Department of Internal Medicine, Ghent University, Ghent, Belgium
12Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
13Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium
14Fondazione di Medicina Molecolare e Terapia Cellulare, Università Politecnica delle Marche, Ancona, Italy
15Department of Dermatology, Hôpital Saint-Louis, Université Paris Cité, Paris, France
16Department of Dermatology, University Hospital of Aarhus, Aarhus, Denmark
17Hamburg Centre for Pediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany
18Department of Dermatology, Dermatology & Skin Care Clinic, Buochs, Switzerland
19Department of Dermatology and Venerology, University of Turku and Turku University Hospital, Turku, Finland
20Department of Dermatology, Venerology and Dermatoclinicology, Semmelweis University, Budapest, Hungary
21The Skin Clinic, Department of Dermato-Allergology, Copenhagen University Hospital, Copenhagen, Denmark
22Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
23Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
24Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy
25Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Saint-André, University of Bordeaux, CNRS, Immuno CencEpT UMR 5164, Bordeaux, France
26Department of Dermatology, Universitätsklinikum Erlangen, Erlangen, Germany
27Department of Dermatology and Venerology, University Hospital Halle, Halle (Saale), Germany
28Private Practice, Medical University of Vienna, Vienna, Austria
29Department of Dermatology, Medical University of Graz, Graz, Austria
30Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, University Hospital Charité—Universitätsmedizin Berlin, Berlin, Germany
31Department of Dermatology and Venerology, and Translational Matrix Biology, University of Cologne, Cologne, Germany

ACKNOWLEDGEMENTS

The authors thank the patients, the investigators and their teams who took part in this study. The authors also ac-
knowledge Antonio Cuzzio, Adina Frasin, Elisabeth Aberer, Camille Frances, Ulrike Just, Aurora Parodi, Antoine Pettit, Annamari Ranki, Júlia Maria Sánchez-Schmidt, Alain Taieb, Nora Wutte, Jean-David Bouaziz, Dorota Krasowska, Cate Orteu for their work on the initial version of these consen-
sus statements, Ara Cho, MD, for her insights on this article, and Hannah Brechka, PhD from Costello Medical, United
Kingdom, for editorial assistance based on the authors’ input and direction. VS is Senior Clinical Investigator of the Research Foundation of Flanders (Belgium; 1.8.029.20N).

FUNDING INFORMATION

Editorial services was provided by Costello Medical, and funded by an independent medical writing grant provided by Mallinkrodt Pharmaceuticals. Mallinkrodt played no role in the development and review of the article, or approval to submit the article for publication. These tasks were solely the responsibility of the authors.

CONFLICT OF INTEREST STATEMENT

Prof. Dr. Robert Knobler received consultancy fees from Therakos/Mallinkrodt and Actelion. Dr. M. Geroldinger-
Simić, PhD, received fees for lectures from Janssen and for attending meetings from Astra Zeneca. Prof. Dr. Alexander
Kreuter received fees for lectures and article preparation from Actelion and had advisory board membership with Sanofi
Pasteur, Merck Sharp and Dohme and AbbVie. Prof. Dr.
Nicolas Hunzelmann received lecture fees from Boehringer and Janssen. Dr. Pia Moinzadeh received lecture fees from Boehringer Ingelheim and received a research grant, con-
sulting honoraria, fees for lectures and participation in re-
view activities from Actelion. Prof. Dr. Franco Rongioletti
received research grants from Abbvie and Almirall. Prof. Dr.
Christopher Denton received research grants from Actelion,
Roche and CSL Behring, and consulting fees from Actelion,
Glaxo Smith Kline, Bayer and Roche. Prof. Dr. Thomas
Krieg, Prof. Dr. L. Mouthon, Prof. Armando Gabrielli, M.
Bagot, Ass. Prof. Dr. A.B Olesen, Prof. Veli-Matti Kähärı,
S. Kärpätä, Prof. Malgorzata Olzewska, Assoc. Prof. Dr.
Jaana Panelius, Pietro Quaglino, Prof. Dr. Julien Seneschal,
M. Sticherling and A. Skrok report no conflicts of interest.
Prof. M. Cutolo received research grants from Boehringer
Ingelheim and Horizon. V. Smith has received grant/research
support to her institution from the Research Foundation
Flanders, Belgian Fund for Scientific Research in Rheumatic
Diseases, Janssen-Cilag and Boehringer-Ingelehim; con-
sulting fees from Boehringer-Ingelehim (payments made
to self and institution) and Janssen-Cilag (payments made
to institution); support for attending meetings and/or travel from Boehringer Ingelheim (payments made to institution). I. Foeldvari has received research grants from Joachim Herz Stiftung and consultancy fees from Eli Lilly, Pfizer, MEDAC, AMGEM and Novartis. Dr. Ahmad Jalili received research grants, consultancy honoraria and fees for lectures and participation in review activities from AbbVie, Almirall, Amgen, Bayer, BioMed, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galderma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Merz Pharma, Novartis, Pfizer, Sanofi, Sandoz and UCB Pharma. Dr. K. Kofod has received fees for lectures from Eli Lilly, Astra Zeneca, Abbvive, Bristol-Myers Squibb, LEO Pharma, Astra Zeneca, Orifarm and Boehringer Ingelheim and fees for consulting from Eli Lilly, Pfizer and Janssen. Prof. Dr. Cord Randkötter has received consulting fees from Boehringer Ingelheim, Biotest AG and Janssen Cilag; payment for lectures from Boehringer Ingelheim, Biotest AG and Janssen Cilag; and support for attending meetings from Boehringer Ingelheim and Pfizer. Prof. Dr. Adrian Tanew has received consulting honoraria or lecture fees from Amgen, Incyte, mesium GmbH and Pelpharam. Prof. Dr. Peter Wolf has received research grants, speaker and/or consulting honoraria, and/or travel refunds from Actavis, Amgen GmbH, Almirall, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Merck Sharp & Dohme, Therakos/Mallinckrodt, Roche, Sandoz, Sanofi, Pfizer and UCB. M. Worm has received honorarium and/or consultation fees from the following companies: Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, DBV Technologies S.A., Immune Therapeutics UK Limited, Regeneron Pharmaceuticals, Inc, Leo Pharma GmbH, Boehringer Ingelheim Pharma GmbH & Co.KG, ALK-Abelló Arzneimittel GmbH, Lilly Deutschland GmbH, Kymab Limited, Amgen GmbH, Abbvie Deutschland GmbH & Co. KG, Pfizer Pharma GmbH, Mylan Germany GmbH (A Viatris Company), AstraZeneca GmbH, Lilly Deutschland GmbH and GlaxoSmithKline GmbH & Co. KG. L. Rudnicka has had an advisory board membership with Pfizer, Sandoz, Sanofi, L’Oreal and has provided medical lectures for Leo Pharma, L’Oreal, UCB and Pierre-Fabre. ICJME Disclosure of Interest form was used to collect conflicts of interest.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ETHICS STATEMENT
The patients in this article have given written informed consent to publication of their case details.

ORCID
Robert Knobler https://orcid.org/0000-0002-7380-7062
Pia Moinzadeh https://orcid.org/0000-0002-8784-8615
Franco Ronzioletti https://orcid.org/0000-0002-2227-581X
Christopher Denton https://orcid.org/0000-0003-3975-8938
Martine Bagot https://orcid.org/0000-0002-1631-5192
Ahmad Jalili https://orcid.org/0000-0002-8349-4530

Pietro Quaglino https://orcid.org/0000-0003-4185-9586
Julien Seneschal https://orcid.org/0000-0003-1139-0908
Adrian Tanew https://orcid.org/0000-0002-4433-2790
Lidia Rudnicka https://orcid.org/0000-0002-8308-1023

REFERENCES


